Overview

Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry

Status:
Unknown status

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

This study is a multi-site study examining the use of Quetiapine XR for psychotic aggression in an acute psychiatric setting. The study aims to demonstrate that management with Quetiapine XR significantly reduces aggressive behaviour in acute patients with psychosis, significantly reduces psychotic symptoms and decreases the requirement for sedation using benzodiazepines.

Phase:

Phase 4

Details

Lead Sponsor:

Bayside Health

Collaborator:

AstraZeneca

Treatments:

Quetiapine Fumarate